33 completed, 19 terminated, 9 withdrawn, 1 active not recruiting. 29 Phase 2, 28 Phase 1, 14 Phase 3.
Follow CTI BioPharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms Pacritinib - T-Cell Neoplasm, Lymphoproliferative Disorders | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 100 | 2023-03-29 | 2026-01-29 |
| Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib - Drug Interactions | Phase 1 | Completed | CTI BioPharma | 60 | 2023-01-03 | 2024-10-17 |
| Study to Evaluate the Safety, Tolerability, and PK of Pacritinib oral dose of 200 mg pacritinib twice daily (BID) - Hepatic Impairment | Phase 1 | Completed | CTI BioPharma | 29 | 2022-12-12 | 2024-10-21 |
| PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer Pacritinib, Placebo - COVID19, COVID-19 | Phase 2 | Terminated | CTI BioPharma | 200 | 2020-05-22 | 2024-06-05 |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) Pacritinib - Myelofibrosis | Phase 2 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 61 | 2018-06-04 | 2022-08-22 |
| Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib Pacritinib - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 2 | Completed | CTI BioPharma | 165 | 2017-07-31 | 2022-06-01 |
| A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Pacritinib, Sirolimus, Tacrolimus - Graft Vs Host Disease, GVHD | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 40 | 2017-06-08 | 2026-04-02 |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Pacritinib, Decitabine - Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia | Phase 1 | Withdrawn | Washington University School of Medicine | 2017-06-01 | 2017-05-08 | |
| Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer Pixantrone - Lymphoma, Solid Tumor (Excluding CNS) | Phase 1 | Withdrawn | CTI BioPharma | 2016-10-24 | 2020-01-29 | |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Pacritinib, Cytarabine, Daunorubicin Hydrochloride - Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 1 | Completed | Bhavana Bhatnagar | 13 | 2016-01-12 | 2019-01-25 |
| A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis Pacritinib - Primary Myelofibrosis | Phase 2 | Withdrawn | Baxalta now part of Shire | 2015-11-30 | 2021-05-05 | |
| Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Pacritinib, 5-azacitidine, Decitabine - Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2015-09-30 | 2018-10-16 |
| Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer Pacritinib - Colorectal Cancer | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2015-09-22 | 2017-05-01 |
| To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI - Healthy | Phase 1 | Completed | CTI BioPharma | 28 | 2015-08-01 | 2023-09-15 |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) Pacritinib, Busulfan, Questionnaires - Myeloproliferative Diseases | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2015-06-15 | 2018-10-30 |
| Study of Clinical Efficacy and Safety of Tosedostat in MDS Tosedostat - Myelodysplastic Syndrome | Phase 2 | Completed | Weill Medical College of Cornell University | 12 | 2015-03-20 | 2018-06-12 |
| Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects Pacritinib - Myelofibrosis | Phase 1 | Completed | CTI BioPharma | 28 | 2015-01-01 | 2020-03-06 |
| Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects Pacritinib, Rifampin, Pacritinib and Rifampin - Healthy Subjects | Phase 1 | Completed | CTI BioPharma | 18 | 2015-01-01 | 2023-09-15 |
| Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects (Treatment A), (Treatment B) - Healthy Subjects | Phase 1 | Completed | CTI BioPharma | 12 | 2015-01-01 | 2023-09-15 |
Showing 20 of 64. Sign in to see all of them.
Primary Myelofibrosis (9) · Lymphoma, Non-Hodgkin (7) · Carcinoma, Non-Small-Cell Lung (6) · Myelodysplastic Syndromes (6) · Myeloproliferative Disorders (6) · Lymphoma, Follicular (5) · Leukemia (4) · Lung Neoplasms (4) · Lymphoma (4) · Multiple Myeloma (4) · Bone Marrow Diseases (3) · Hematologic Diseases (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myelomonocytic, Chronic (3) · Polycythemia Vera (3)
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (21) · paclitaxel poliglumex (12) · Arsenic Trioxide (9) · Rituximab (8) · pixantrone (8) · Carboplatin (4) · Gemcitabine (4) · Azacitidine (3) · Decitabine (3) · Paclitaxel (3) · fludarabine (3) · Cyclophosphamide (2) · Dexamethasone (2) · Radiotherapy (2) · Vinorelbine (2)
United States (54) · France (7) · Germany (7) · Italy (7) · United Kingdom (7) · Hungary (6) · Russia (5) · Belgium (4) · Canada (4) · Netherlands (4) · Romania (4) · Bulgaria (3) · Czechia (3) · Poland (3) · Ukraine (3)
Carolyn Paradise, MD (2) · John D. Hainsworth, MD (2) · Kelly Whitehurst, MD (2) · Scott C. Stromatt, MD (2) · Simran Singh (2) · Agustin Garcia, MD (1) · Barone C., M.D. (1) · Benjamin R Tan, M.D. (1) · Beth Ziemba (1) · Bhavana Bhatnagar, DO (1) · Bob Wright, PM (1) · Brenda Garrison (1) · Camille Abboud, M.D. (1) · Chetan Jeurkar, DO (1)
PMID 33275766, PMID 34551507, PMID 16651647, PMID 18520802, PMID 18594318, PMID 21681734, PMID 22652183, PMID 23946328, PMID 27093976, PMID 29382747, PMID 31879945, PMID 33043735, PMID 33753457, PMID 36469321, PMID 39400386, PMID 42316774
2015 (1), R01CA265929 (1), R01HL133823 (1)